PURPOSE: To determine distribution and deposition of Technosphere® Insulin (TI) inhalation powder and the rate of clearance of fumaryl diketopiperazine (FDKP; major component of Technosphere particles) and insulin from the lungs. METHODS: Deposition and distribution of (99m)pertechnetate adsorbed onto TI immediately after administration using the MedTone® inhaler was quantified by gamma-scintigraphy. Clearance from the lungs was studied in a second experiment by serial bronchoalveolar lavage (BAL) after administration of TI inhalation powder and assay of the recovered fluid for FDKP and insulin. RESULTS: Following inhalation, ~60% of radioactivity (adsorbed on TI) emitted from the inhaler was delivered to the lungs; the remainder of the emitted dose was swallowed. Clearance from the lung epithelial lining fluid (ELF) of FDKP and insulin have a half-life of ~1 hour. CONCLUSION: TI inhalation powder administered via the MedTone inhaler was uniformly distributed throughout the lungs; ~40% of the initial cartridge load reached the lungs. Insulin and FDKP are quickly cleared from the lungs, mainly by absorption into the systemic circulation. The terminal clearance half-life from the lung ELF, estimated from sequential BAL fluid measurements for both components, was ~1 hour. Since there is an overnight washout period, the potential for accumulation on chronic administration is minimal.
PURPOSE: To determine distribution and deposition of Technosphere® Insulin (TI) inhalation powder and the rate of clearance of fumaryl diketopiperazine (FDKP; major component of Technosphere particles) and insulin from the lungs. METHODS: Deposition and distribution of (99m)pertechnetate adsorbed onto TI immediately after administration using the MedTone® inhaler was quantified by gamma-scintigraphy. Clearance from the lungs was studied in a second experiment by serial bronchoalveolar lavage (BAL) after administration of TI inhalation powder and assay of the recovered fluid for FDKP and insulin. RESULTS: Following inhalation, ~60% of radioactivity (adsorbed on TI) emitted from the inhaler was delivered to the lungs; the remainder of the emitted dose was swallowed. Clearance from the lung epithelial lining fluid (ELF) of FDKP and insulin have a half-life of ~1 hour. CONCLUSION: TI inhalation powder administered via the MedTone inhaler was uniformly distributed throughout the lungs; ~40% of the initial cartridge load reached the lungs. Insulin and FDKP are quickly cleared from the lungs, mainly by absorption into the systemic circulation. The terminal clearance half-life from the lung ELF, estimated from sequential BAL fluid measurements for both components, was ~1 hour. Since there is an overnight washout period, the potential for accumulation on chronic administration is minimal.
Authors: Elizabeth Potocka; James P Cassidy; Pamela Haworth; Douglas Heuman; Sjoerd van Marle; Robert A Baughman Journal: J Diabetes Sci Technol Date: 2010-09-01
Authors: Klaus Rave; Susanne Bott; Lutz Heinemann; Sue Sha; Reinhard H A Becker; Susan A Willavize; Tim Heise Journal: Diabetes Care Date: 2005-05 Impact factor: 19.112
Authors: K Rave; E Potocka; L Heinemann; T Heise; A H Boss; M Marino; D Costello; R Chen Journal: Diabetes Obes Metab Date: 2009-05-19 Impact factor: 6.577
Authors: Dick B S Brashier; Anjan Khadka; Tejus Anantharamu; Ashok Kumar Sharma; A K Gupta; Sushil Sharma; N Dahiya Journal: J Pharmacol Pharmacother Date: 2015 Jul-Sep
Authors: Halis Kaan Akturk; Janet K Snell-Bergeon; Amanda Rewers; Leslie J Klaff; Bruce W Bode; Anne L Peters; Timothy S Bailey; Satish K Garg Journal: Diabetes Technol Ther Date: 2018-09-15 Impact factor: 6.118